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A B S T R A C T
Background
Bronchodilators are a central component for treating exacerbations of chronic obstructive pulmonary disease (COPD) all over the
world. Clinicians often use nebulisers as a mode of delivery, especially in the acute setting, andmany patients seem to benefit from them.
However, evidence supporting this choice from systematic analysis is sparse, and available data are frequently biased by the inclusion
of asthma patients. Therefore, there is little or no formal guidance regarding the mode of delivery, which has led to a wide variation in
practice between and within countries and even among doctors in the same hospital. We assessed the available randomised controlled
trials (RCTs) to help guide practice in a more uniform way.
Objectives
To compare the effects of nebulisers versus pressurised metered dose inhalers (pMDI) plus spacer or dry powder inhalers (DPI) in
bronchodilator therapy for exacerbations of COPD.
Search methods
We searched the Cochrane Airways Group Trial Register and reference lists of articles up to 1 July 2016.
Selection criteria
RCTs of both parallel and cross-over designs. We included RCTs during COPD exacerbations, whether measured during hospitalisation
or in an outpatient setting. We excluded RCTs involving mechanically ventilated patients due to the different condition of both patients
and airways in this setting.
Data collection and analysis
Two review authors independently assessed studies for inclusion, extracted data and assessed the risk of bias. We report results with
95% confidence intervals (CIs).
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Main results
This review includes eight studies with a total of 250 participants comparing nebuliser versus pMDI plus spacer treatment.We identified
no studies comparing DPI with nebulisers. We found two studies assessing the primary outcome of ’change in forced expiratory volume
in one second (FEV1) one hour after dosing’. We could not pool these studies, but both showed a non-significant difference in favour
of the nebuliser group, with similar frequencies of serious adverse events. For the secondary outcome, ’change in FEV1 closest to one
hour after dosing’: we found a significant difference of 83 ml (95% CI 10 to 156, P = 0.03) in favour of nebuliser treatment. For the
secondary outcome of adverse events, we found a non-significant odds ratio of 1.65 (95% CI 0.42 to 6.48) in favour of the pMDI plus
spacer group.
Authors’ conclusions
There is a lack of evidence in favour of one mode of delivery over another for bronchodilators during exacerbations of COPD. We
found no difference between nebulisers versus pMDI plus spacer regarding the primary outcomes of FEV1 at one hour and safety.
For the secondary outcome ’change in FEV1 closest to one hour after dosing’ during an exacerbation of COPD, we found a greater
improvement in FEV1 when treating with nebulisers than with pMDI plus spacers.
A limited amount of data are available (eight studies involving 250 participants). These studies were difficult to pool, of low quality
and did not provide enough evidence to favour one mode of delivery over another. No data of sufficient quality have been published
comparing nebulisers versus DPIs in this setting. More studies are required to assess the optimal mode of delivery during exacerbations
of COPD.
P L A I N L A N G U A G E S U M M A R Y
Bronchodilators delivered by nebuliser versus inhalers for lung attacks of chronic obstructive pulmonary disease
Review question
When someone is suffering from a lung attack due to chronic obstructive pulmonary disease (COPD), are inhalers with a spacer as
good as nebulisers?
Background
Someone experiencing a lung attack suffers from shortness of breath because the airways are narrowed. Bronchodilators are a type of
drug that helps to open these airways, but the best way to deliver them to the body is unknown. We searched for the best delivery
device during lung attacks, focusing on whether there is a difference between wet nebulisers, which allow people to breathe in medicine
as a mist using a mask or mouthpiece, compared with inhalers.
What evidence did we find?
We found eight studies including 250 participants in a search of the available studies up to 1 July 2016. All of the studies took place
in a hospital.
What do the studies tell us?
The primary outcomes of the review showed no difference between the inhaler with a spacer and the nebuliser. However, in our
secondary outcomes, we found some evidence that nebuliser treatment improves lung function more than inhalers with a spacer, but
the quality and quantity of the data is limited. We found no difference between the therapies in terms of side effects or for reducing
breathlessness. There are no studies available testing dry powder inhalation against a nebuliser.
Conclusion
Due to the low quality and quantity of the data, it is not clear whether nebulisers or inhalers with spacers are better for lung attacks.
We found no difference between an inhaler with a spacer and the nebuliser in lung function after one hour or in unwanted side effects
during lung attacks of COPD. The secondary outcome for lung function did favour nebulisers over inhalers with a spacer.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Bronchodilators delivered by nebuliser versus pM DI with spacer for exacerbations of COPD
Patient or population: part icipants with an exacerbat ion of COPD; people with asthma excluded f rom our analysis
Settings: t reatment was allowed at home or in the clinic or hospital
Intervention: nebuliser
Comparison: pMDI with spacer




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
pM DI with spacer Nebuliser
Change in FEV1 1 h af-
ter dosing in ml
The mean change in
FEV1 1 h af ter dosing
in the pMDI group was
103 ml
The mean change in
FEV1 1 h af ter dosing in
the nebuliser group was
36 ml more (f rom 38 ml











Change in FEV1 closest
to 1 h after dosing in
ml
The mean change in
FEV1 closest to 1 h af -
ter dosing in the pMDI
group is93 ml
The mean change in
FEV1 closest to 1 h af ter
dosing in the nebuliser
groups was 83 ml more







score during the first
24 h after dosing
The mean change in
dyspnoea score dur-
ing the f irst 24 h af -
ter dosing−1.28 points
on the Borg scale
(lower score indicates
reduced dyspnoea)
The mean change in
dyspnoea score during
the f irst 24 h af ter dos-
ing was 0.12 points
worse (0.56 better to 0.













































































































































The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; OR: odds rat io; ml: millil it res; FEV1 : f orced expiratory volume in 1 second; pM DI: pressurised metered dose inhaler.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aDowngraded for sample size (only one small study included in the analysis) (−2) and indirectness (e.g. older trials, so
devices used may not be relevant to clinical pract ice today, and heterogeneity in dose between the groups) (−1)
bDowngraded for sample size of the included trials (−1) and indirectness (e.g.older trials, so devices used may not be relevant



























































































































B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is one of the
most important respiratory diseases and the third leading cause
of death worldwide (WHO 2014). It is generally caused by ex-
posure to smoke or pollution. It is characterised by lung function
decline and is associated with a decreased quality of life. Patients
with COPD may have episodes with worsening of respiratory
symptoms that require additional treatment (Burge 2003). These
COPD exacerbations are the main driver of quality of life and sur-
vival in COPD. Exacerbations consist of a heterogenous spectrum
of pathobiological changes compared to stable COPD, includ-
ing inflammation, infection and hyperinflation (Lopez-Campos
2015; Van Geffen 2015a; Van Geffen 2016). Exacerbations ac-
count for between 34% and 70% of all costs incurred in COPD
(Oostenbrink 2004).
Description of the intervention
Bonchodilation is important in the medical treatment of COPD,
both in stable state and during exacerbations (GOLD 2015). The
choice of drug, dose and device all contribute to the success of
inhaled medication in their own way, but remarkable differences
exist in the prescribing habits of individual clinicians in all of these
areas.
The inhaled bronchodilators used in COPD are short-acting
beta2-agonists (SABA), long-acting beta2-agonists (LABA), and
short-and long-acting anticholinergics. These are administered
through various devices (GOLD 2015).
Many clinicians choose to treat patients with nebulisers, especially
in the acute setting, and many patients claim to benefit from them
(Zheng 2014). However, evidence supporting this choice from
systematic analysis is lacking, and the available data are frequently
biased by the inclusion of asthma patients (Greene 1988; Jasper
1987; Mandelberg 1997; Turner 1997).
This Cochrane review will assess the evidence available on nebu-
lised bronchodilator treatment versus delivery by pressurised me-
tered dose inhalers (pMDI) with spacer or by dry powder in-
halers (DPI) for acute exacerbations of COPD. We published our
planned strategy and methods earlier as a protocol (Van Geffen
2015b).
How the intervention might work
Prior research has clearly established the benefit of bronchodila-
tion in treating patients with COPD. Several systematic reviews
have shown this for bronchodilators in a stable state of COPD
(Appleton 2006; Kew 2014). During exacerbations, experts also
recommend the use of bronchodilation (GOLD 2015). Hence,
bronchodilators are common in treatment of COPD exacerba-
tions all over the world. However, less is known about the best
mode of delivery for these treatments, especially during exacerba-
tions. Important features known to affect the deposition include
particle size, choice of the device, respiration pattern and inhala-
tion technique. During exacerbations of COPD, nebulisers, as
well as pMDIs and DPIs, have been shown to be useful in deliv-
ering medication into the lungs (Demoly 2014; Mazhar 2008).
However, there are differences between device types, which may
lead to differences in efficacy. For instance, the use of nebulisers is
more time-consuming compared with pMDI/DPI, and patients
require a better technique to inhale their bronchodilators by DPI
and especially pMDI without spacer. Due to the nature of exacer-
bations, the best choice of a delivery method for bronchodilators
may differ from stable state.
Why it is important to do this review
Although there is consensus on the use of bronchodilators, there
has been little attention to themode of delivery. As a consequence,
wide variations in practice exist between and within countries and
even among doctors in the same hospital. We assessed the available
RCTs to help guide practice in a more uniform way.
O B J E C T I V E S
To compare the effects of nebulisers versus pressurised metered
dose inhalers (pMDI) plus spacer or dry powder inhalers (DPI) in
bronchodilator therapy for exacerbations of COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of both parallel
and cross-over designs.
Types of participants
We included studies in participantswith an exacerbationofCOPD
receiving treatment at home, in the clinic or in hospital. We ex-
cluded RCTs involving mechanically ventilated patients due to the
different condition of both patients and airways in this setting.
We also excluded people with asthma from our analysis.
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Types of interventions
We included trials comparing a bronchodilatormedicationby neb-
uliser with the same bronchodilator medication by either pMDI
(with or without spacer) or DPI. We allowed co-interventions in-
cluding inhaled steroids.
Types of outcome measures
Primary outcomes
1. Change in forced expiratory volume in one second (FEV1),
one hour after dosing
2. Serious adverse events
Secondary outcomes
1. Change in peak FEV1
2. Change in FEV1 closest to one hour after dosing
3. Change in FEV1 at other time points during the first 24
hours after dosing
4. Change in dyspnoea score during the first 24 hours after
dosing
5. Change in quality of life on the first day of dosing
6. Admission rates
7. Time in hospital emergency department
8. Length of hospital stay
9. Change in oxygen saturation
10. Hospital readmission in 30 days
11. Adverse events/side effects
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Information Spe-
cialist for the Cochrane Airways Group. The CAGR contains
trial reports identified through systematic searches of bibliographic
databases including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO, and handsearching of respiratory journals and
meeting abstracts (please see Appendix 1 for further details). We
searched all records in the CAGR using the search strategy in
Appendix 2 up to 1 July 2016.
We also searched ClinicalTrials.gov (clinicaltrials.gov) and the
World Health Organization (WHO) trials portal (who.int/ictrp/
en/).We searched both databases from their inception 1 July 2016,
and we imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary trials and review arti-
cles for additional references. We searched for errata and retrac-
tions from included trials published in full-text on PubMed (
www.ncbi.nlm.nih.gov/pubmed) to 1 July 2016.
Data collection and analysis
Selection of studies
Two review authors (WG and HK) independently screened titles
and abstracts for inclusion of all the potential trials identified as a
result of the search and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. Based on the consensus
reached, we retrieved the full texts for assessment. Two review au-
thors independently screened the full-text records and identified
trials for inclusion. We reported the reasons for excluding the in-
eligible trials in a ’Characteristics of excluded studies’ table. We
resolved any disagreements through discussion or, if required, we
consulted a third review author. We identified and excluded du-
plicates and collated multiple reports of the same trial so that each
trial rather than each report was the unit of interest in the review.
We recorded the selection process in sufficient detail to complete
a PRISMA flow diagram (Figure 1).
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Figure 1. Study flow diagram
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Data extraction and management
We used a data collection form, which we piloted on one included
study, to record trial characteristics and outcome data. Two review
authors extracted the following trial characteristics from included
trials.
1. Methods: trial design, total duration of trial, details of any
’run-in’ period, number of trial centres and location, trial setting,
withdrawals and date of trial.
2. Participants: N, mean age, age range, sex, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, and inclusion and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors extracted outcome data from the included
trials. We noted in the ’Characteristics of included studies’ table
if outcome data was not reported in a usable way. We resolved
disagreements by consensus or by involving a third review author.
One review author, WG, transferred data into Review Manager
(RevMan 2014). We double-checked that data were entered cor-
rectly by comparing the data presented in the systematic review
with the trial reports. A second review author checked the papers’
trial characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors assessed risk of bias for each trial using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).We resolved any disagreements by
discussion or by involving a third review author. We assessed the
risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as either ’high’, ’low’, or
’unclear’ and provided a quote from the trial report or a justifica-
tion for our judgment in the ’Risk of bias’ table. We summarised
the ’Risk of bias’ judgements across different trials for each of the
domains listed. We considered blinding separately for different
key outcomes where necessary (e.g. for unblinded outcome assess-
ment, risk of bias for all-cause mortality may be very different than
for a patient- reported pain scale). Where information on risk of
bias related to unpublished data or correspondence with a trialist,
we noted this in the ’Risk of bias’ summary (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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When considering treatment effects, we took into account the risk
of bias for the trials that contributed to that outcome.
Assessment of bias in conducting the systematic
review
The review was conducted according to the published protocol
(Van Geffen 2015b), and we report any deviations from it in the
’Differences between protocol and review’ section.
Measures of treatment effect
Weanalysed dichotomous data as odds ratios (OR) and continuous
data as mean difference (MD) or standardised mean difference
(SMD). We entered data presented as a scale with a consistent
direction of effect. To analyse the cross-over trials included in
Analyses 1.1, 2.2 and 2.3, we used the generic inverse variance
(GIV) method.
We undertook meta-analyses only where it was meaningful to
do so, that is, if the treatments, participants, and the underlying
clinical question were similar enough for pooling to make sense.
We narratively described skewed data reported as medians and
interquartile ranges.
For these studies, we expected to have to standardise the results of
the studies to a uniform scale before combining them. The SMD
expresses the size of the intervention effect in each study relative
to the variability observed in that study. However, we could not
use the SMD due to the cross-over design of some of the included
studies. In the studieswhere thiswas the case, we decided topresent
the data as a mean difference only.
Unit of analysis issues
If we had identified both cluster RCTs and individual RCTs, we
planned to synthesise the acquired data. We planned to combine
the results if we only detected a little heterogeneity between the
trial designs, and we considered bias based on the choice of ran-
domisation unit to be unlikely.Otherwise, wewould have adjusted
the sample sizes or standard errors using the methods described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Dealing with missing data
When we thought missing data could introduce serious bias, we
explored the impact of including such studies in the overall assess-
ment of results by performing a sensitivity analysis.
The studies we examined for the primary outcomes mostly had
relatively short-term outcomes. We found some missing data for
the primary outcomes. In the case of Turner 1988, we managed
to obtain original data, and we were able to calculate some of the
missing data. We did not impute or extrapolate existing data.
Assessment of heterogeneity
We used the I2 statistic to assess heterogeneity among the studies
in each analysis. Where we identified substantial heterogeneity, we
have reported it and explored possible causes.
Assessment of reporting biases
Had we been able to pool more than 10 studies, we would have
created and examined funnel plots to explore possible small trial
and publication biases. However, we did not reach a pool of 10
studies.
Data synthesis
We used a random-effects model and performed a sensitivity anal-
ysis with a fixed-effect model. We used the standard deviations
to standardise the mean differences to a single scale and compute
trial weights.
Subgroup analysis and investigation of heterogeneity
We planned to analyse data according to bronchodilators
used,mechanism (anticholinergic or beta-adrenergic), and short-
acting versus long-acting beta2-agonists, analysing subgroups sep-
arately for SABA, LABA, SAMA, LAMA, and SABA/LAMA com-
binations. We also planned to analyse the data from single dose
trials in the primary outcomes, and to analyse a subgroup of mul-
tiple treatment (doses) trials for the primary and secondary out-
comes. However, due to the small number of studies included in
our review, subgroup analyses (e.g. for dose or device) were un-
derpowered. Therefore, we decided to assess all data pooled.
Sensitivity analysis
We assessed the risk of introducing bias due to missing data
through a sensitivity analysis of our primary outcomes by compar-
ing Berry 1989 and Mazhar 2007 with the other studies assessed
as being at low risk of bias.
’Summary of findings’ table
We created a ’Summary of findings’ table using both the pri-
mary and secondary outcomes (Summary of findings for the main
comparison). We used the five GRADE considerations (trial lim-
itations, consistency of effect, imprecision, indirectness, and pub-
lication bias) to assess the quality of the body of evidence as it
relates to the trials contributing data to the meta-analyses for the
prespecified outcomes. We used methods and recommendations
described in Section 8.5 and Chapter 12 of Higgins 2011, using
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GRADEpro software (GRADEpro GDT). We detailed all deci-
sions to downgrade or upgrade the quality of trials in the ’Sum-
mary of findings’ table footnotes and made comments to aid read-
ers’ understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
We found 1082 records from the Cochrane Airways Group Spe-
cialised Register. After scanning titles and abstracts, we selected 44
for full-text review. In addition, we identified 277 records from
ClinicalTrials.gov (clinicaltrials.gov) and 80 from theWHO trials
portal (www.who.int/ictrp/en/).Of these, we selected only one ad-
ditional ongoing study (NCT02291016), with no available data.
We found 12 additional references through other sources.We anal-
ysed those 56 articles in detail, as reported in Figure 1.
Included studies
See the ’Characteristics of included studies’ for full details. We
identified eight studies with an appropriate design to evaluate our
predefined outcomes. A total of 250 participants withCOPDwere
randomised to doses of aerosol with an inhaler plus spacer or a
nebuliser treatment. Six out of the eight included studies reported
excluding participants experiencing themost severe exacerbations,
using criteria such as pH < 7.30 kPa, inability to perform spirome-
try or stand unsupported, respiratory failure or requiring mechan-
ical ventilation. We identified no studies reporting on dry pow-
der inhaler versus a nebuliser. We included studies with single or
multiple dose and cross-over designs. The studies took place in
hospital settings in the United States (Berry 1989; Maguire 1991;
Moss 1985; Shortall 2002; Turner 1988), the United Kingdom
(Higgins 1987; Mazhar 2007), and Turkey (Mirici 2004). The
studies used different beta2-agonists, anticholinergics, pMDIs,
spacers and nebulisers. We noticed a difference in dosage ratio
between the pMDI/spacer and nebuliser in the studies. This ratio
varies from 1:1 in Higgins 1987 to 1:11.5 in Maguire 1991.
Excluded studies
See the ’Characteristics of excluded studies’ table for full details.
Most commonly, we excluded studies in the ventilation setting,
studies without an appropriate comparator to answer our hypoth-
esis and studies mixing results for asthma and COPD.
Risk of bias in included studies
See Figure 2 for the ’Risk of bias’ summary. For each study, we
describe the ’Risk of bias’ assessment in the ’Characteristics of
included studies’ table. The methodological quality of the studies
included varied. Most of the studies did not describe the method
of sequence generation, allocation concealment, or blinding of
outcome assessment. None of the included studies reported the
use of an intention-to-treat analysis or a power analysis. One study
did not adequately describe the use of a spacer in their manuscript
(Moss 1985). However, we decided to include Moss 1985 in our
analysis based on the following arguments: we estimated that they
did use a spacer in their study; according to our protocol, we had
agreed to include studies that did not use a spacer; based on the
reported trial design, we assessed this study to be of sufficient
quality to be included in this analysis; and the study has been
included in another meta-analysis (Turner 1997).
Allocation
Only Mirici 2004 and Turner 1988 reported the use of a com-
puter-generated list of random numbers; the other six included
studies may have been influenced by selection bias. Mirici 2004
adequately described their allocation blinding, and based on the
overall quality of Turner 1988, we deemed the risk for selection
bias due to allocation concealment methods to be low.
Blinding
Three studies were not blinded (Maguire 1991; Mazhar 2007;
Shortall 2002), so the risk of performance and detection bias in
these studies is high. The other studies were all double-blinded.
Incomplete outcome data
The risk of attrition bias was high in three of the studies using
peak expiratory flow (PEF) measurements in the analysis, because
FEV1 measurements after hospitalisation were not available for all
participants (Mirici 2004;Moss 1985; Shortall 2002). Moss 1985
was never published as a full paper. Shortall 2002 reported that 4
participants of the oral/pMDI group and 12 in the intravenous/
nebuliser group did not complete the trial. It remains unclear why
these participants dropped out and what caused the imbalance
between the groups in the number of drop-outs.
Selective reporting
We observed a risk of selective reporting bias in three studies where
authors described a change in FEV1 in the methods but did not
report it (Higgins 1987;Mirici 2004;Moss 1985).Mirici 2004 did
not report FEV1 and forced vital capacity (FVC) measurements
after hospitalisation. The abstract of Moss 1985 was not published
as a full paper, leading to a high risk of reporting bias.
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Other potential sources of bias
An important issue to consider is a difference in dose ratio between
the pMDI/spacer and the nebuliser in the studies. This ratio varies
from 1:1 in Higgins 1987 to 1:11.5 in Maguire 1991.
Effects of interventions
See: Summary of findings for the main comparison
Primary outcomes
Change in FEV1 one hour after dosing
We analysed the change in FEV1 one hour after dosing in Berry
1989 and Mazhar 2007. Due to different measurement units and
the cross-over design of the studies, we could not pool them. A
separate analysis of both studies showed a non-significant differ-
ence in favour of the nebuliser group. Mazhar 2007 found a mean
absolute increase in FEV1 of 4.3% ± 4.8 in the nebuliser group,
compared with 2.6% ± 3.3 in the pMDI group. Berry 1989 found
a mean relative increase in FEV1 of 16.7% ± 17 in the nebuliser
group compared with 13.4% ± 20.5 for the pMDI group. Change
in FEV1 one hour after dosing did not show a significant differ-
ence between the pDMI and nebuliser group (MD36ml, 95%CI
−38 to 110, N = 40, Analysis 1.1). Most other included studies
reported two separate values for FEV1 instead of a change in FEV1
at this time point, making meta-analysis of their data impossible.
Serious adverse events
There were no significant differences in the occurrence of serious
adverse events between the two delivery methods in the two trials
that reported on this outcome (Mirici 2004; Turner 1988). Turner
1988 reported none. Mirici 2004 reported that two participants
developed a pneumothorax and one participant required mechan-
ical ventilation in the nebuliser group, and three participants de-
veloped a pneumothorax in the pMDI group (Figure 3).
Figure 3. Forest plot of comparison: Primary endpoint: Nebuliser vs pMDI/DPI, outcome: Serious adverse
events.
Secondary outcomes
Change in peak FEV1
There were no data available regarding change in peak FEV1.
Change in FEV1 closest to one hour after dosing
We pooled reported data change in millilitres. According to our
protocol, we could include cross-over designs (Van Geffen2015b).
This resulted in the fact that studies reporting a different scale of
data could not be included in the meta-analysis. The forest plot
shows a significant difference of 83 ml (95% CI 10 to 156, P =
0.03) in favour of the nebuliser treatment (Figure 4). If multiple
time points were available, we included the time points closest to
one hour of dosing. Moss 1985 measured FEV1 at 20 minutes
after the dose, while we included the measurements from Turner
1988 at a 30 minute time point. The measurements from Berry
1989 were performed at one hour. Shortall 2002 did not report
data about the timing of measurements; however, based on their
trial design, we assumed they were performed at a sufficient time
point to include them in this analysis. Due to a different unit
of reporting, we could not include data from Maguire 1991 and
Mazhar 2007 in this meta-analysis. However, their results also
show a non-significant difference in favour of the nebuliser group.
We calculated the standard error for the GIV analysis from the
formula in Section 16.4.6.1 of Higgins 2011.
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Figure 4. Forest plot of comparison: Secondary endpoint: Nebuliser vs pMDI/DPI, outcome: Change in
FEV1 (mL) closest to one hour after dosing.
Change in FEV1 at other time points during the first 24
hours after dosing
We were not able to find data about additional time points other
than those reported in the analyses above. Therefore, we did not
deem a separate analysis to be meaningful for this outcome.
Change in dyspnoea score during the first 24 hours after
dosing
Based on data from two studies measuring dyspnoea with Borg’s
scale, we found no significant change in dyspnoea score (Berry
1989; Shortall 2002). One additional study also used this scale,
reporting no significant difference between the groups (Turner
1988). However, we were not able to obtain the raw data for this
outcome to recalculate their numbers to our previously defined
outcome. Based on the included data, we found a non-significant
difference of 0.12 points (95% CI −0.56 to 0.79; P = 0.73) in
favour of the pMDI group (Figure 5).
Figure 5. Forest plot of comparison: Secondary endpoint: Nebuliser vs pMDI/DPI, outcome: Change in
dyspnoea score in the first 24 hours after dosing.
Change in quality of life on the first day of dosing
There were no data available about change in quality of life on the
first day of dosing.
Admission rates
We found no significant difference in admission rate. Turner 1988
took place at the emergency department, reporting two admissions
in both the pMDI and nebuliser group. We nevertheless found a
non-significant difference in favour of the nebuliser group (OR:
0.80, 95%CI 0.09 to 7.00) because the nebuliser group contained
slightly more participants.
Time in hospital emergency department
Although Turner 1988 was performed at the emergency depart-
ment, it did not report on time in the emergency department.
Thus we could not extract data about this outcome.
Length of hospital stay
We found no significant difference in hospital stay in the one study
reporting this outcome: Shortall 2002 reported a non-significant
difference in favour of the pMDI group of 0.80 days (95% CI
−1.05 to 2.65, P = 0.40).
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Change in oxygen saturation
Mirici 2004 reported a change in oxygen saturation at several time
points after inclusion. There were no significant changes at 30
minutes after the first dose or at the other reported time points (6
h, 24 h, 48 h or 10 d).
Hospital readmission in 30 days
There were no data available about hospital readmission rates in
30 days.
Adverse events/side effects
We found no significant differences between the groups concern-
ing adverse events in the three studies reporting on this outcome
(Higgins 1987; Mirici 2004; Turner 1988). Turner 1988 reported
two adverse events in the nebuliser group; however, they did not
explain the nature of these events. One participant in Higgins
1987 developed a marked fall in saturation from 88% to 73% 15
minutes after taking the nebuliser treatment. As stated earlier in
the primary outcome section, Mirici 2004 reported two partici-
pants developing a pneumothorax and one participant requiring
mechanical ventilation in the nebuliser group, and three partici-
pants developing a pneumothorax in the pMDI group (Figure 6).
Figure 6. Forest plot of comparison: 2 Secondary endpoint: Nebuliser vs pMDI/DPI, outcome: 2.10 Adverse
events/side effects.
D I S C U S S I O N
Summary of main results
There is a lack of evidence favouring one mode of bronchodilator
delivery over another during exacerbations of COPD. We found
no difference between nebulisers and pMDI plus spacer regard-
ing the primary outcomes FEV1 at one hour and safety. The sec-
ondary outcome ’change in FEV1 closest to one hour after dosing’
showed a greater improvement in FEV1 when treating with nebu-
lisers than with pMDI plus spacers. A limited amount of data are
available (eight studies involving 250 participants). These studies
were difficult to pool. There were no available study data to enable
us to include data about DPIs in our analysis.
Bronchusobstruction
The search for better parameters for acute, severe COPD exacer-
bations is ongoing (Van Geffen 2015a), but for now, FEV1 con-
tinues to be an important parameter in clinical trials for COPD
exacerbations. This review assessed change in FEV1 at several time
points. We found no significant differences between the pMDI
and nebuliser group for a change in FEV1 at one hour after dosing,
but we could not pool the available data. The secondary outcome,
’change in FEV1 closest to one hour after dosing’, showed a greater
improvement in FEV1 in the nebuliser group than in the pMDI
plus spacers group. Overall, there is a lack of evidence favouring
one mode of delivery over another for bronchodilators during ex-
acerbations of COPD with regard to bronchus obstruction.
Adverse events
Three studies reported on adverse events (Higgins 1987; Mirici
2004; Turner 1988). This is the first time the data have been
pooled and assessed systematically. Adverse and especially serious
adverse events might influence the device choice for physicians
when treating patients with COPD exacerbations. However, with
current available data in this systematic review, we found no signif-
icant differences between pMDI and nebuliser treatment. Over-
all, there is a lack of evidence favouring one mode of delivery for
bronchodilators over another during exacerbations of COPDwith
regard to adverse events.
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Dyspnoea and quality of life
Patient-reported outcomes are becoming more important in cur-
rent practice. Patient-reported outcomes include scoring of dysp-
noea and quality of life. The analysis of dyspnoea showed no sig-
nificant differences between pMDI and nebuliser treatment. We
did not identify any data about quality of life. Overall, there is a
lack of evidence favouring one mode of delivery for bronchodila-
tors over another during exacerbations of COPD with regard to
dyspnoea and quality of life.
Clinically important outcomes
This systematic review assessed additional clinically important
outcomes, used both by physicians and policymakers on a daily
basis. We were surprised by the lack of data about admission rates,
time in the hospital emergency department, length of hospital
stay, and hospital readmission within 30 days. These are perhaps
parameters that have only recently become more important, and
additionally necessitate longer trials. Overall. there is a lack of ev-
idence favouring one mode of delivery for bronchodilators over
another during exacerbations of COPD with regard to these out-
comes.
Overall completeness and applicability of
evidence
The overall completeness of the evidence is low. Due to differ-
ences in outcome reporting we could not calculate the change in
parameters from all studies. The evidence gathered related only to
the comparison of nebulisers versus pMDIs. We found no studies
investigating DPIs versus nebulisers using the same substance, nor
studies with nebulised long-acting bronchodilators. Data about
important clinical parameters, hospital readmission in 30 days,
change in peak FEV1′ and change in quality of life were not avail-
able. Participants in the included studies were all treated in a hospi-
tal setting rather than at home. Turner 1988 reported on an emer-
gency department setting, from which most participants were not
admitted. We recognise that the setting in which a patient receives
treatment may have an impact on the choice of treatment mode,
beyond concerns solely about the efficacy of the method. The
paucity of data in this review has not allowed us to comment on
the effect of the trial setting on the outcomes. We noticed a lack of
standardised definitions in both COPD and exacerbations, which
might influence the generalisability of the findings, although this
lack of standardised definitions is also present in regular clinical
practice. Thus, it is not entirely clear whether our results apply
to all patients who present to a hospital with an exacerbation of
COPD.
Additional studies could prove useful in providing further evidence
towards the difference we signalled in bronchodilator effects in
favour of the nebuliser treatment. However, readers should keep in
mind that the mean clinically important difference for the FEV1
is generally reported to be 100 to 140 ml (Cazzola 2008; Jones
2014).
Many practitioners commonly prescribe nebulisers for the acute
exacerbation of COPD. Based on the results of our review, there
is no evidence to either support or refute this practice. This might
influence the applicability of the evidence; however, given the lack
of evidence provided in this review, it is even more important to
adequately assess the individual patient, the available modes of
nebulisers and the available pMDIs and spacers. There are several
important differences between different types of modern nebulis-
ers, for instance regarding inhaled dose, delivered dose and the use
of the compressor (De Boer 2003; Le Brun 1999). In the absence
of good quality evidence, such an assessment might provide guid-
ance to select the optimal treatment for each patient.
Quality of the evidence
We used the GRADE assessment to qualify the amount of evi-
dence of the outcomes, reporting this in the Summary of findings
for the main comparison. Overall the quality of the evidence was
low and sometimes even lacking. The studies that were included
in this review are relatively small, and we downgraded the quality
of the outcomes to reflect this. Especially for the primary outcome
measuring FEV1 at one hour, we could only include one older trial
(Berry 1989). We therefore downgraded the evidence for this out-
come. Heterogeneity varied across individual outcomes, ranging
from I2 = 0% to I2 for = 47% for change in FEV1 (ml) closest to
one hour after dosing.
The evidence was relatively old, with studies performed from at
least 9 years and up to 31 years prior to this systematic review.
This might influence the results, since modern nebulisers, pMDIs
and DPIs may work in a different way than the ones used 30 years
ago.
It is important to note the lack of standardised dose of bron-
chodilators between the different designs. Although actual lung
deposition is generally held to be lower by nebuliser than by pMDI
when using the same dose in both devices, good data are sparse.
We noticed a significant variation in dose between the studies.
Additionally, the type of nebuliser, compressor and pMDI used in
trials will influence the actual lung deposition (De Boer 2003; Le
Brun 1999; Mazhar 2007). This might influence results, although
it is unclear to what extent. We downgraded the quality of the
evidence due to the combination of relatively old studies and dose
variation.
Potential biases in the review process
Apotential bias in our review process is publication bias.We found
several studies reported only as abstracts. Although we tried, we
could not retrieve a full data set from the study authors for several
reasons. The data reported in the abstracts were not sufficient to
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allow recalculation for our outcomes, except in the case of the
study by Moss 1985.
Agreements and disagreements with other
studies or reviews
Although the data for the primary outcome did not show signif-
icant differences, this systemic review suggests for the first time
that treatment with nebulisers during an exacerbation of COPD
may improve FEV1 more than pMDI with a spacer. However, it is
very difficult to interpret this result correctly due to the previously
discussed bias. We therefore concur with the earlier findings from
Turner 1997 and Dolovich 2005. They did not find significant
differences and concluded that there is not enough evidence to
favour a mode of delivery for bronchodilators during exacerba-
tions of COPD. Both reviews used asthma patients in their anal-
ysis, and both focused on FEV1 or peak flow. A systematic review
in mechanically ventilated patients with a need for aerosol bron-
chodilator therapy found no difference in bronchodilator effects,
although they were only able to pool two studies with 28 partici-
pants in total for this outcome (Holland 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to inconclusive findings for our primary outcomes and all
but one of our secondary outcomes, risk of bias, and relatively low
numbers of studies and participants (eight studies involving 250
participants), the existing published data do not provide enough
evidence to firmly favour one mode of delivery for bronchodila-
tors over another during exacerbations of COPD. One secondary
outcome suggests that treatment with nebulisers during an exac-
erbation of COPD slightly outperforms pMDI plus spacer with
regard to improving FEV1; however, this finding should be in-
terpreted with care. Limited data about nebulisers versus pMDIs
plus spacer are available. No data of sufficient quality have been
published comparing nebulisers in this setting versus DPIs. We
did not identify any studies of nebulised long-acting drugs. Most
studies tested on one day only, in a cross-over design.
Implications for research
More studies are required to assess the optimal mode of delivery
during exacerbations of COPD. In particular, data about DPIs
versus nebulisers are lacking. There seems to be a larger effect on
FEV1 with the nebuliser. However, larger studies could shed more
light on this and should take into account the considerable dif-
ference in the total administered dose between nebulisation and
pMDI, and indeed the differences between different nebuliser de-
signs and inhalers devices. The outcomes of these studies have tra-
ditionally focused at bronchodilating effects. Future studies should
also assess different parameters such as adverse events, dyspnoea
and quality of life. Patients, both in the acute setting and even in
a stable state of COPD, seem to be more satisfied with nebulised
administration than can be understood from the bronchodilatory
data. Further research may be required to investigate the accept-
ability of different drug delivery modes in patients who may be
accustomed to receiving nebulised treatment during an exacerba-
tion. In times of strain on the medical system and its costs, length
of stay and time to readmission would be valuable additional pa-
rameters for trials to consider. Investigators should report data
about patients with COPD, asthma or an overlap syndrome sep-
arately. Future research evaluating nebuliser treatment compared
with pMDI or DPI during COPD exacerbations should report
findings as a change in means with standard error or standard de-
viation, or studies should provide sufficient data in the study re-
port to enable calculation of these values. This will enable a meta-
analysis of the study findings. We would also advise researchers to
perform a power analysis when planning any new trials.The value
of long-acting bronchodilators in the treatment of exacerbations,
as well as their optimal modes of delivery, is totally unknown but
would be valuable to study, especially since they have been shown
to reduce hyperinflation and improve dyspnoea in stable state and
are the standard of care after discharge (Van Geffen 2015a).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berry 1989
Methods Cross-over RCT
Power analysis: not presented
Participants Location: Long Beach, CA, USA
20 participants aged 60-91, mean 67.9 (SD 7.1)
Baseline characteristics: comparable
Setting: admitted through emergency department
COPD definition: long history of chronic airflow obstruction and smoking
Exclusion criteria: pH < 7.30 kPa
Interventions 2 treatment blocks on a single day separated by 4 h with salbutamol, either by pMDI
and spacer or by nebuliser, and placebo in the other device
Beta2 -agonist: salbutamol (albuterol)
pMDI: brand not reported
Spacer: InspirEase
Nebuliser: Airlife misty nebuliser
Dosage ratio spacer/nebuliser: 1:7
Co-interventions: aminophylline IV, corticosteroids IV
Medication adherence rates: not reported
Outcomes FEV1, FVC, Borg scale
Time points: at baseline and 1 hour after treatment with each device
Notes Funded by a grant from the Schering Group and VA Research Service
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote “We undertook a study to .... using
a more typical inpatient schedule of drug
administration with a randomised double
blind cross-over protocol.”
Allocation concealment (selection bias) Unclear risk Randomisation protocol not described
Comment: unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote “double blind cross-over protocol.”
Comment: Probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “double blind cross-over proto-
col”
Comment: probably done
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Berry 1989 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: We detected no missing data
Selective reporting (reporting bias) Low risk For all groups all data was reported
Other bias Unclear risk COPDwas defined only as a long history of
chronic airflow obstruction and smoking.
No definition of COPD exacerbation was
provided
Only males were included, potentially lim-
iting the extrapolation of results to males
only. Possible sequence effect in cross-over
trial not reported on
Comment: this might lead to bias
Higgins 1987
Methods Cross-over RCT
Power analysis: not presented
Participants Location: Oxford, England
20 participants, mean age 71.1 years (SEM: 1.5)
Baseline characteristics: comparable
Setting: admitted in hospital
COPD definition: not reported
Exclusion criteria: not reported
Interventions Measurements on 1 day, 3 sessions, 4 h apart. Sessions were 4 mg terbutaline either by
nebuliser or pMDI with Nebuhaler and placebo in the other device and sessions with
placebo in both devices in random sequence
Beta2 -agonist: terbutaline
pMDI: brand not reported
Spacer: Nebuhaler
Nebuliser: brand not reported
Dosage ratio spacer/nebuliser: 1:1
Co-interventions: not reported
Medication adherence rates: not reported
Outcomes Changes in FEV1, % changes in tcCO2, % change in SaO2
Time points: FEV1 was measured at baseline and 20 minutes after treatment, tcCOand
SaO2 were measured continously during 30 minutes after treatment
Notes Financial support by Astra Pharmaceuticals. Author Cookson received a WA and MG
Saw Medical Research Fellowship
Risk of bias
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Higgins 1987 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “the order of the sessions was
randomised”
Allocation concealment (selection bias) Unclear risk Randomisation protocol not described
Comment: unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotation: “double Blind”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “double Blind”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: we detected no missing data
Selective reporting (reporting bias) High risk Change in FEV1 was described in the
Methods but not reported
Other bias Unclear risk COPD was not defined; no definition of
COPD exacerbation was provided. Possi-
ble sequence effect in cross-over trial not
reported upon
Comment: this might lead to bias
Maguire 1991
Methods Cross-over RCT
Power analysis: was not presented
Participants Location: Valhalla, NY, USA
7 participants with COPD; mean smoking 82.8 pack-years and onset of symptoms after
age 40. 10 asthma participants were also included, but were reported separately
Baseline characteristics: not reported separately for the COPD group; comparable be-
tween trial arms
Setting: hospital
COPD definition: 1990 ATS definition. Two of the COPD group had bronchitis and
did not meet the ATS criteria of that time. Exacerbation was defined as acute onset of
increasing respiratory symptoms
Exclusion criteria: not able to stand unsupported next to the bed or to perform spirometry
Interventions Metaproterenol in pMDI-Spacer (2 x 0.65 mg), or handheld nebuliser (15 mg). Each
participant received both devices. Treatment was separated by 2.96 ± 0.27 h (mean ±
SEM)
Beta2 -agonist: metaproterenol
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Maguire 1991 (Continued)
pMDI: brand not reported
Spacer: InspirEase, Key Pharmaceuticals, Miami, FL (USA)
Nebuliser: Travenol, Travenol corporation, Edison, NJ (USA)
Dosage ratio spacer/nebuliser: 1:11.5
Co-interventions: unclear
Medication adherence rates: not reported
Outcomes Change in FEV1, FVC and FEF 25-75, FEV1, FVC and FEF 25-75
Time points: each participant tested 4 times (30 min before and after each treatment)
Notes Trial was supported by a grant from the National Institute of Health (NIHR)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “randomly selected”
Randomisation protocol not described
Allocation concealment (selection bias) High risk Randomisation protocol not described
Comment: given probable lack of blinding,
this also probably not done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: we detected no missing data
Selective reporting (reporting bias) Low risk Comment: we detected no missing out-
comes
Other bias High risk Compared to the other studies, a very high
dosagemedication by nebuliser was admin-
istered (ratio spacer/nebuliser 1:11.5). Pos-
sible sequence effect in cross-over trial not
reported upon
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Mazhar 2007
Methods Cross-over RCT
Power analysis: not presented
Participants Location: Huddersfield, England
11 participants,19 asthma participants were also included and reported separately
Baseline characteristics: reported to be comparable but not specified
Setting: ward
COPD definition: not reported
Exclusion criteria: respiratory failure
Interventions On the 2nd and 4th day of admission, regular terbutaline dose was replaced by a salbuta-
mol study dose. Five 100 µg salbutamol doses were inhaled from a metered dose inhaler
plus spacer (pMDI + SP) or 5 mg was nebulised (NEB)
Beta2 -agonist: salbutamol
pMDI: Ventolin Evohaler; GlaxoSmithKline, Brentford, UK
Spacer: Volumatic (GlaxoSmithKline) large volume spacer
Nebuliser: Sidestream chamber (Respironics, Tangmere, UK)
Dosage ratio spacer/nebuliser: 1:10
Co-interventions: terbutaline, other were not reported
Medication adherence rates: not reported
Outcomes Urinary salbutamol excretion, change in FEV1
Time points: 30 min and 24 h (salbutamol excretion) and baseline and after 1 hour for
FEV1
Notes Source of funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “The inhalation method to be
used on the study days was randomized.”
Randomisation protocol not described
Allocation concealment (selection bias) High risk Randomisation protocol not described
Comment: Given probable lack of blind-
ing, this also probably not done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding or the use of placebo was not de-
scribed in the manuscript
Comment: probably not done
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding or the use of placebo was not de-
scribed in the manuscript
Comment: probably not done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none detected
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Mazhar 2007 (Continued)
Selective reporting (reporting bias) Low risk Comment: none detected
Other bias Low risk No data provided regarding possible se-
quence effect in cross-over trial
Mirici 2004
Methods Randomised, double dummy, parallel group trial.
Power analysis: not reported
Participants Location: Erzum, Turkey
48 participants were randomised
Baseline characteristics: comparable except for pH. Participants in the nebuliser group
had a significantly lower pH than the pMDI group
Setting: hospital
COPD definition: 1995 ATS guidelines, known FEV1/ FVC < 70% and maximum
FEV1 < 80% Definition of the exacerbation: one of the following: increased dyspnoea,
increased production and purulence, leading to a change of treatment
Exclusion criteria: presence of other conditions such as cystic fibrosis, asthma, severe
bronchiectasia, pneumonia, severe hypertension, and severe exacerbation requiring in-
vasive or noninvasive mechanical ventilation. Patients who were not using the pMDI/
spacer with the appropriate technique were also not included the study
Interventions Participants were randomised to pMDI/spacer group receiving 100 µg salbutamol and 20
µg ipratropium (4 times 4 puffs) and placebo nebuliser or the nebuliser group receiving




Spacer: yes, type not reported
Nebuliser: not reported
Dosage ratio spacer/nebuliser: 1:6.25
Co-interventions: oral steroids, theophylline, antibiotics and supplementary oxygen
Medication adherence rates: not reported
Outcomes Cost effectiveness, FEV1 (not reported), PEF, PaO2, PaCO2, SaO2, pH
Time points: baseline, 30 min, 24 h, 48 h and 10 d
Notes Source of funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation protocol described a com-
puter-generated list of random numbers
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Mirici 2004 (Continued)
Allocation concealment (selection bias) Low risk Quotation: “randomization was performed
using unmarked, ordered, sealed en-
velopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: fully blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quotation: “PEFR measurements were
used in the analysis, because FEV1 mea-
surements after hospitalisation were not
available for all patients.”
Selective reporting (reporting bias) High risk Quotation: “PEFR measurements were
used in the analysis, because FEV1 mea-
surements after hospitalization were not
available for all patients.” FVC was not
reported although baseline measurements
were performed
Other bias Unclear risk The groups were relatively small (21 vs 22
participants)
Comment: small and power calculation
was not provided, leaving room for a type
II error
Moss 1985
Methods Double blind randomised cross-over design
Power analysis: not reported
Participants Location: St John’s Mercy Medical Center, St Louis, MO, USA
15 participants were randomised in a cross-over design
Baseline characteristics: stated to be comparable
Setting: hospital
COPD definition: not provided
Exclusion criteria: not provided
Interventions Participants were treated with either 15 mg metaproterenol by compressor driven neb-
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Moss 1985 (Continued)
Nebuliser: not reported
Dosage ratio MDI/nebuliser: 1:7.69
Co-interventions: not reported
Medication adherence rates: not reported
Outcomes Change in FEV1 and subjective improvement by a numerical scale
Time points: 20 min after treatment with each device
Notes This study was only published as an abstract. Source of funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “randomized”
Randomisation protocol not described
Allocation concealment (selection bias) Unclear risk Randomisation protocol not described
Comment: unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotation “double Blind”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation “double Blind”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk Data is not provided, the abstract was never
published as a full paper
Selective reporting (reporting bias) High risk Comment: the trial was not reported as a
full-text paper. Also the data about subjec-
tive improvement were not reported other
than it was not significantly different
Other bias High risk No definition of COPD, exacerbation or
other details were provided
Shortall 2002
Methods RCT
Power analysis: not reported
Participants Location: Eastern Maine Medical Center and St Joseph Hospital, Bangor, ME, USA
50 participants were randomised; however, only 34 were analysed. Dropouts were im-
balanced (4 in pMDI group and 12 in the nebuliser group)
Baseline characteristics: comparable
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Shortall 2002 (Continued)
Setting: hospital
COPD definition: FEV1 < 60% predicted, FEV1/FVC < 60% after bronchodilators.
Postbronchodilator < 15 % increase in FEV1. Exacerbations were defined as an increase
of dyspnoea, cough or mucus production plus one or more of the following: inadequate
response to outpatient treatment, marked decrease in exercise capacity, inability to eat
or sleep due to dyspnoea, worsening hypoxaemia and a new or worsening hypercapnia
Exclusion criteria: acute pneumonia, status asthmaticus, bronchiectasis, cystic fibrosis,
upper airway obstruction, left ventricular dysfunction, positive blood culture, (non)
invasive ventilation, inability to cooperate with pMDI or mask inhalation
Interventions Participants were randomised to either an oral/pMDI regimen or an IV/nebuliser regime
The oral/pMDI regimen was: methylprednisolone; 40 mg per os every 6 h until wheeze-
free, then 40mg per os per day. Albuterol; 1 puff per 30 s the first 2min, then 1 puff every
min up to 20 puffs per 4 h and 1 puff every h as needed until alleviation of dyspnoea.
Ipratropium; 1 puff per 30 s the first 2 min, 1 puff every min, up to 8 puffs per 4 h, and
1 puff every h as needed. Cefuroxim 500 mg per os twice a day
The IV/nebuliser regime was methylprednisolone; 40 mg intravenously each 6 h until
wheeze-free, then 40 mg per os per day. Nebulised 2.5 mg albuterol and 0.5 mg iprat-





Spacer: AeroChamber, Monaghan Medical Plattsburgh, NY, USA
Nebuliser: Airlife mistyneb nebulizer (Allegiance Healthcare, McGraw, IL, USA)
Dosage ratio spacer/nebuliser: not reported
Co-interventions: theophylline and supplementary oxygen
Medication adherence rates: not reported
Outcomes FEV1 (L), change in FEV1 (L), mean length of stay, treatment failure, change in Borg
scale
Time points: not reported
Notes Investigators did not report SDs or confidence intervals, and we could not reach them
to obtain these. With help from our statistician, we calculated the SDs (assuming they
were equal in both groups)
The raw data provided us with a mean change in FEV1 in litres of 0.12 (oral/pMDI
group, N = 19) and 0.13 in the (IV/NEB group, N = 15)
Based on the formula t = (y1 − y2)/ (SD *
√
(1/N1+1/N2)) t = 0.15 based on the P value
provided by the article, y = change. Thiswould make y1 = 0.12, y2 = 0.13, N1 = 19 and
N2 = 15; we calculated the SD to be 0.193. We used a similar calculation to calculate the
SD for the Borg score. Here twas 0.41 based on the provided P value. SD was calculated
to be 1.55. For length of stay t = 0.85 SD was calculated to be 2.73.
Risk of bias
Bias Authors’ judgement Support for judgement
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Shortall 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quotation: “randomized”
Randomisation protocol not described
Allocation concealment (selection bias) High risk Randomisation protocol not described
Comment: Given lack of blinding, probably not
done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Quotation: 4 participants of the oral/pMDI group
and 12 of the IV/nebuliser group did not complete
the trial. It is unclear why the patients in each group
dropped out
Selective reporting (reporting bias) Low risk Comment: none detected
Other bias High risk The treatment groups differed not only by nebu-
lised vs pMDI device for inhalation, but also by
IV vs oral administration of systemic steroids and
antibiotics, rendering all comparisons difficult to
interpret. Comment: the timing of the performed
lung function measurements was not reported
58% of the potential study participants were not
studied for several reasons
Turner 1988
Methods RCT
Power analysis: not reported
Participants Location: San Francisco, CA, USA
22participants:mean age 55 years (SD4), pMDI-spacer group; 57 years (SD3), nebuliser
group. 53 asthma patients were also included and reported separately
Baseline characteristics: comparable
Setting: emergency room
COPD definition: ≥10 pack-years of smoking and onset of symptoms ≥ age 30
Exclusion criteria: younger than 18, older than 75, acute myocardial infarction, heart
failure, intubation, inability to perform an FEV1, allergy towards metaproterenol or
pregnant
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Turner 1988 (Continued)
Interventions Randomly assigned to 3 x 0.65 mg metaproterenol via pMDI + spacer + placebo, or
nebuliser metaproterenol 15 mg + placebo. Each treatment was given 3 times at 30 min
intervals
Beta2 -agonist: metaproterenol
pMDI: brand not reported
Spacer: InspirEase, Key Pharmaceuticals, USA
Nebuliser: Acorn II, Marquest Medical, USA
Dosage ratio spacer/nebuliser: 1:7.7
Co-interventions: oxygen, IV steroids; theophylline was withheld
Medication adherence rates: not reported
Outcomes FEV1, Borg scale, pulse, respiratory rate, blood pressure
Time points: baseline, after 30 and 90 minutes
Notes Source of funding not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation protocol was described in unpub-
lished data quote: “therapy was then determined .
. . by a random list of numbers”
Comment: probably done
Allocation concealment (selection bias) Low risk Randomisation protocol was described in unpub-
lished data quote: “therapy was then determined .
. . by a random list of numbers”
Comment: based on the quality of the trial and
procedures for a trial performed in this decade, we
estimate the risk to be low
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotation: “double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quotation: “double blind”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: none detected
Selective reporting (reporting bias) Low risk Change in FEV1 was not reported; we obtained
access to the full data and calculated this ourselves
Other bias High risk COPD was defined only as ≥10 pack years of
smoking and onset of symptoms ≥ age 30, and
therefore less than fully clearly separated from
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Turner 1988 (Continued)
asthma
Comment: this might lead to bias, especially since
asthmatics tend to have larger bronchodilator re-
sponses
ATS: American Thoracic Society;COPD: chronic obstructive pulmonary disease; FEF: forced expiratory flow; FEV1 : forced expiratory
volume in 1 second; FVC: forced vital capacity; IV: Intravenous;PaCO2 : partial pressure of carbon dioxide in arterial blood; PaO2
: partial pressure of oxygen in arterial blood; PEF(R): peak expiratory flow (rate); pH: potential of hydrogen; pMDI: pressurised
metered-dose inhaler; SaO2 : symbol for the percentage of oxygen saturation of arterial blood; SEM: standard error of the mean;
SD: standard deviation;tcCO2: transcutaneous carbon dioxide.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelrahim 2011 Non-invasive ventilation setting and no pMDI or DPI was used as comparator
Bai 1993 Mechanical ventilation setting
Broeders 2004 No nebuliser was used as comparator
Brunetti 2015 No pMDI or DPI was used as comparator
Carpenter 2008 Trial was performed in stable state only
Cazzola 2002a No nebuliser was used as comparator
Cazzola 2002b No nebuliser was used as comparator
Chu 1989 Trial was performed in stable state only
Dhand 2002 No abstract or full-text available. Prof Dhand informed us that this trial was performed in stable state
Duarte 2000 Mechanical ventilation setting
Finnerty 1999 No abstract or full-text available; authors could not be reached
Foresi 2002 No full-text available; authors could not be reached. Based on FEV1/FVC ratio, not all participants had COPD
and reported stable state only
Formgren 1994 No nebuliser was used as comparator
Greene 1988 Combination of asthma and COPD exacerbations. No results for COPD were reported
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(Continued)
Guerin 1999 Mechanical ventilation setting
Haynes 2012 No pMDI or DPI was used as comparator
Ikeda 1994 Trial was performed in stable state only
Jasper 1987 Combination of asthma and COPD exacerbations. Insufficient results for COPD were reported
Kaminski 1997 Trial was performed in stable state only
Lai 1990 Trial was performed in stable state only
Lees 1980 Trial was performed in stable state only
Li 2011 No full-text available; authors could not be reached
Mandelberg 1997 Combination of asthma and COPD exacerbations. No separate results for COPD were reported
Marlin 1986 Trial was performed in stable state only
Marta 1997 Stable state, combination of asthma and COPD
Martos 1990 No full-text available; authors could not be reached
Mestitz 1988 Trial was performed in stable state only. Combination of asthma and COPD
Mouloudi 1998 Non-invasive ventilation setting and no nebuliser was used as comparator
Nair 2005 No pMDI or DPI was used as comparator
Numata 2002 The trial lacked specific data for the nebuliser group. We contacted Prof Schwartzman; however the raw data
has been lost
Pappalettera 2005 No full-text available; authors could not be reached
Petrova 2001 No full-text available; authors could not be reached
Qian 2008 No pMDI or DPI was used as comparator
Quinn 2014 Trial was performed in stable state only, no nebuliser was used as comparator
Rebuck 1987 No pMDI or DPI was used as comparator
Schleufe 2004 No nebuliser was used as comparator
Segreti 2013 Different types of bronchodilators used
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(Continued)
Summer 1989 Combination of asthma and COPD exacerbations. No results for COPD were reported
Willaert 2002 Different types of bronchodilators used
Wisthal 1997 Trial was performed in stable state only
Wu 2012 Mechanical ventilation setting
Zanen 1997 Trial was performed in stable state only
COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; FEV1 : forced expiratory volume in 1 second; FVC: forced
vital capacity; pMDI: pressurised metered-dose inhaler
Characteristics of ongoing studies [ordered by study ID]
NCT02291016
Trial name or title COPD aerosol study comparing the efficacy of nebulizers versus dry powder inhalers
Methods Registered, currently running and unpublished randomised interventional trial
Participants Location: University of Tennessee,TN, USA
Target: 30 participants
Setting: unknown
COPD definition: FEV1/FVC ratio ≤ 70%
Interventions Comparison of dosage administered via a nebuliser versus dosage administered via a dry powder inhaler. 12
µg formoterol with the dry powder inhaler and 20 µg (solution form) of formoterol with the nebuliser
Beta2 -agonist: formoterol
DPI: brand not reported
Nebuliser: brand not reported
Dosage ratio DPI/nebuliser: 1:1.667
Outcomes The difference between the values of area under the response curve for FEV1 from baseline through 4 h (AUC
FEV1 0 to 4 h),
Starting date 2015
Contact information Contact: Lauren Davis; lsdavis@mc.utmck.edu; principal investigator: Rajiv Dhand, MD
Notes NCT02291016
AUC: area under the curve; FEV1 : forced expiratory volume in 1 second; FVC: forced vital capacity
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D A T A A N D A N A L Y S E S
Comparison 1. Nebuliser vs pMDI: primary outcomes




participants Statistical method Effect size
1 Change in FEV1 (ml) 1 h after
dosing
1 Mean Difference (Random, 95% CI) 36.0 [-37.69, 109.
69]
2 Serious adverse events 2 70 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.18, 5.53]
Comparison 2. Nebuliser vs pMDI: secondary outcomes




participants Statistical method Effect size
1 Change in peak FEV1 [%] 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Change in FEV1 (ml) closest to
1 h after dosing
4 Mean Difference (Random, 95% CI) 82.98 [10.30, 155.
67]
3 Change in dyspnoea score in the
first 24 h after dosing
2 Mean Difference (Fixed, 95% CI) 0.12 [-0.56, 0.79]
4 Change in quality of life on the
first day of dosing
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Admission rates 1 22 Odds Ratio (M-H, Random, 95% CI) 0.8 [0.09, 7.00]
6 Time in hospital emergency
department
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Length of hospital stay 1 34 Mean Difference (IV, Fixed, 95% CI) 0.80 [-1.05, 2.65]
8 Change in oxygen saturation 1 42 Mean Difference (IV, Fixed, 95% CI) 4.0 [-4.04, 12.04]
9 Hospital readmission in 30 d 0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events/side effects 3 110 Odds Ratio (M-H, Random, 95% CI) 1.65 [0.42, 6.48]
36Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.1. Comparison 1 Nebuliser vs pMDI: primary outcomes, Outcome 1 Change in FEV1 (ml) 1 h
after dosing.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 1 Nebuliser vs pMDI: primary outcomes
Outcome: 1 Change in FEV1 (ml) 1 h after dosing





IV,Random,95% CI IV,Random,95% CI
Berry 1989 (1) 36 (37.6) 100.0 % 36.00 [ -37.69, 109.69 ]
Total (95% CI) 100.0 % 36.00 [ -37.69, 109.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours pMDI with spacer Favours nebuliser
(1) Mean FEV1 rose by 139ml on nebuliser and 103ml on pMDI and spacer
Analysis 1.2. Comparison 1 Nebuliser vs pMDI: primary outcomes, Outcome 2 Serious adverse events.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 1 Nebuliser vs pMDI: primary outcomes
Outcome: 2 Serious adverse events








Mirici 2004 3/24 3/24 100.0 % 1.00 [ 0.18, 5.53 ]
Turner 1988 0/12 0/10 Not estimable
Total (95% CI) 36 34 100.0 % 1.00 [ 0.18, 5.53 ]
Total events: 3 (Nebuliser), 3 (pMDI with spacer)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours nebuliser Favours pMDI with spacer
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Analysis 2.2. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 2 Change in FEV1 (ml)
closest to 1 h after dosing.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 2 Change in FEV1 (ml) closest to 1 h after dosing





IV,Random,95% CI IV,Random,95% CI
Berry 1989 36 (37.6) 34.6 % 36.00 [ -37.69, 109.69 ]
Moss 1985 170 (55) 24.6 % 170.00 [ 62.20, 277.80 ]
Shortall 2002 10 (66.7) 19.6 % 10.00 [ -120.73, 140.73 ]
Turner 1988 126 (62.5) 21.2 % 126.00 [ 3.50, 248.50 ]
Total (95% CI) 100.0 % 82.98 [ 10.30, 155.67 ]
Heterogeneity: Tau2 = 2566.60; Chi2 = 5.67, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
Favours pMDI with spacer Favours nebuliser
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Analysis 2.3. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 3 Change in dyspnoea score
in the first 24 h after dosing.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 3 Change in dyspnoea score in the first 24 h after dosing





IV,Fixed,95% CI IV,Fixed,95% CI
Berry 1989 0.35 (0.45) 58.6 % 0.35 [ -0.53, 1.23 ]
Shortall 2002 -0.21 (0.5357) 41.4 % -0.21 [ -1.26, 0.84 ]
Total (95% CI) 100.0 % 0.12 [ -0.56, 0.79 ]
Heterogeneity: Chi2 = 0.64, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours nebuliser Favours pMDI with spacer
Analysis 2.5. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 5 Admission rates.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 5 Admission rates








Turner 1988 2/12 2/10 100.0 % 0.80 [ 0.09, 7.00 ]
Total (95% CI) 12 10 100.0 % 0.80 [ 0.09, 7.00 ]
Total events: 2 (Nebuliser), 2 (pMDI with spacer)
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Nebuliser Favours pMDI with spacer
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Analysis 2.7. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 7 Length of hospital stay.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 7 Length of hospital stay





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Shortall 2002 15 5.1 (2.73) 19 4.3 (2.73) 100.0 % 0.80 [ -1.05, 2.65 ]
Total (95% CI) 15 19 100.0 % 0.80 [ -1.05, 2.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours nebuliser Favours pMDI with spacer
Analysis 2.8. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 8 Change in oxygen
saturation.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 8 Change in oxygen saturation





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mirici 2004 21 8 (17.6) 21 4 (6.6) 100.0 % 4.00 [ -4.04, 12.04 ]
Total (95% CI) 21 21 100.0 % 4.00 [ -4.04, 12.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours pMDI with spacer Favours Nebuliser
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Analysis 2.10. Comparison 2 Nebuliser vs pMDI: secondary outcomes, Outcome 10 Adverse events/side
effects.
Review: Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD
Comparison: 2 Nebuliser vs pMDI: secondary outcomes
Outcome: 10 Adverse events/side effects








Higgins 1987 1/20 0/20 17.5 % 3.15 [ 0.12, 82.16 ]
Mirici 2004 3/24 3/24 63.7 % 1.00 [ 0.18, 5.53 ]
Turner 1988 2/12 0/10 18.7 % 5.00 [ 0.21, 117.21 ]
Total (95% CI) 56 54 100.0 % 1.65 [ 0.42, 6.48 ]
Total events: 6 (Nebuliser), 3 (pMDI with spacer)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours nebuliser Favours pMDI with spacer
A P P E N D I C E S
Appendix 1. Sources and search methods for the CAGR
Electronic searches: core databases
Database Frequency of search




41Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD (Review)




Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
COPD search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.






Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomized or randomised).ab,ti.
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11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify relevant trials from the CAGR
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW








#14 inhal* NEAR3 device*:TI,AB,KW
#15 MeSH DESCRIPTOR Nebulizers and Vaporizers Explode All
#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 #6 AND #16
[Note: in search line #4, MISC1 denotes the field in the record in which the reference has been coded for condition, in this case, COPD]
C O N T R I B U T I O N S O F A U T H O R S
WG performed the search, screened titles and abstracts, screened the full-text records and identified trials for inclusion, performed data
extraction, transferred data into RevMan and analysis, assessed risk of bias and wrote the first draft of the manuscript.
WD reviewed the manuscript and functioned as third review author during discussions.
DJS reviewed the manuscript and functioned as third review author during discussions.
HK screened titles and abstracts, screened the full-text records and identified trials for inclusion, extracted outcome data, double checked
transferred data in RevMan, checked papers’ trial characteristics, assessed risk of bias and reviewed the manuscript.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We published our planned strategy and methods earlier as a protocol (Van Geffen 2015b).
We updated the Background section to include the most recent literature.
We excluded RCTs involving asthma patients and mechanically ventilated patients due to the differences in patients, inhalation and
airways in this setting. We did not describe this in our protocol because we did not expect these trials to turn up during our search.
There are separate Cochrane reviews for these groups (Cates 2013; Holland 2013).
As reported in the protocol, safety is an important outcome of the review; to clarify this, we added safety assessment as an objective to
the review.
Initially, we aimed only to include full-text papers; however, based on both Cochrane policy and optimal data gathering, we decided
to include abstracts in the review.
The included studies defined COPD in several different ways although we anticipated all studies to follow the American Thoracic
Society (ATS) or Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. We reported the definition used by each
study in the ’Characteristics of included studies’ table, and we reported it specifically in our risk of bias tables if we considered that the
definition introduced bias.
We initially formulated one of our secondary outcomes, ’Change in FEV1 closest to one hour after dosing’, as within six hours after
dosing. However, one study did not report the time of their measurements (Shortall 2002), so we cannot claim with certainty that it
happened within six hours after dosing. Nevertheless, one can assume based on their manuscript that the measurements actually were
performed within six hours. For this reason we chose not to exclude this report for the meta-analysis.
Due to the cross-over design of the included trials, we used the GIV method to analyse outcomes 1.1, 2.2 and 2.3.
We had planned several subgroup analyses, but due to the small number of included studies, we were not able to provide a meaningful
pooled analysis by mechanism (anticholinergic or beta-adrenergic), by short-acting versus long-acting agent, or to analyse subgroups
44Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
separately for SABA, LABA, SAMA, LAMA, and SABA/LAMA combinations. We could not perform a stratification for treatment
setting (hospital or outpatient) based on the included studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dry Powder Inhalers; ∗Metered Dose Inhalers [adverse effects]; Bronchodilator Agents [∗administration & dosage]; Disease Pro-
gression; Forced Expiratory Volume; Inhalation Spacers [adverse effects]; Pulmonary Disease, Chronic Obstructive [∗drug therapy;
physiopathology]; Randomized Controlled Trials as Topic; Time Factors
MeSH check words
Humans
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